---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-344549"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2026-08-11T20:01:42+00:00"
generated_at: "2026-08-11T20:03:37.565171+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AN2 Q2 net loss $8.2M; PV Phase 2 to start Q4 2026, Chagas Phase 2 by year-end

## Summary
- Q2 2026 net loss $8.2M vs $6.5M YoY; R&D $6.0M, G&A $2.9M; cash $79.9M, runway into 2029.
- Epetraborole Phase 2 (EBO-PV-201) in polycythemia vera: IND filing Q3 2026, enrollment Q4 2026, US/Australia sites.
- M. abscessus Phase 2 investigator-initiated trial enrollment ongoing; topline results expected late 2027.
- Chagas: positive NHP (100% parasite elimination) and Phase 1 data for AN2-502998; Phase 2 initiation planned late 2026.
- Second boron-based development candidate (solid tumors) expected to advance by end of 2026.

## SEC filing metadata
- accession: 0001193125-26-344549
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2026-08-11T20:01:42+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312526344549/0001193125-26-344549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312526344549/antx-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-344549
- JSON: https://secwatch.observer/filing/0001193125-26-344549.json
- Plain text: https://secwatch.observer/filing/0001193125-26-344549.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.